

## DAFTAR PUSTAKA

- Adeyinka, A. and Bashir, K., 2019. Tumor Lysis Syndrome. In *StatPearls [Internet]*. **StatPearls Publishing**.
- Al Bagshi, M., 2013. Tumor Lysis Syndrome in Children with Acute Leukemia: Incidence and Outcome. **Journal of Applied Hematology**, 4(3), p.100.
- Alakel, N., Middeke, J.M., Schetelig, J. and Bornhauser, M., 2017. Prevention and Treatment of Tumor Lysis Syndrome, and the Efficacy and Role of Rasburicase. **OncoTargets and Therapy**, 10, p.597.
- Andreoli, S.P., 2009. Acute Kidney Injury in Children. **Pediatric Nephrology**, 24(2), p.253.
- Arozal, W., Watanabe, K., Veeraveedu, P., Ma, M., Thandavarayan, R.A., Sukumaran, V., Suzuki, K., Kodama, M. and Aizawa, Y., 2010. Protective Effect of Carvedilol on Daunorubicin-Induced Cardiotoxicity and Nephrotoxicity in Rats. **Toxicology**, 274(1-3), pp.18-26.
- Ayla, S., Seckin, I., Tanriverdi, G., Cengiz, M., Eser, M., Soner, B.C. and Oktem, G., 2011. Doxorubicin Induced Nephrotoxicity: Protective Effect of Nicotinamide. **International Journal of Cell Biology**.
- Bagnoux, A.S., Kuster, N., Cavalier, E., Piéroni, L., Souweine, J.S., Delanaye, P. and Cristol, J.P., 2018. Serum Creatinine: Advantages and Pitfalls. **Journal of Laboratory and Precision Medicine**.
- Belay, Y., Yirdaw, K. and Enawgaw, B., 2017. Tumor Lysis Syndrome in Patients with Hematological Malignancies. **Journal of Oncology**, 2017, pp 1-9.
- Benn, C.L., Dua, P., Gurrell, R., Loudon, P., Pike, A., Storer, R.I. and Vangjeli, C., 2018. Physiology of Hyperuricemia and Urate-Lowering Treatments. **Frontiers in Medicine**, 5, p.160.
- Bickert, B. and Reilly, A., 2004. Pediatric Tumor Lysis Syndrome. **Journal of Pharmacy Practice**, 17(6), pp.447-454.
- Burns, C.M. and Wortmann, R.L., 2012. Latest Evidence on Gout Management: What the Clinician Needs to Know. **Therapeutic Advances in Chronic Disease**, 3(6), pp.271-286.
- Burns, R.A., Topoz, I. and Reynolds, S.L., 2014. Tumor Lysis Syndrome: Risk Factors, Diagnosis, and Management. **Pediatric Emergency Care**, 30(8), pp.571-576.

- Cairo, M.S., Coiffier, B., Reiter, A., Younes, A. and TLS Expert Panel, 2010. Recommendations for the Evaluation of Risk and Prophylaxis of Tumour Lysis Syndrome (TLS) in Adults and Children with Malignant Diseases: an Expert TLS Panel Consensus. **British Journal of Haematology**, 149(4), pp.578-586.
- Cammalleri, L. and Malaguarnera, M., 2007. Rasburicase Represents a New Tool for Hyperuricemia in Tumor Lysis Syndrome and in Gout. **International Journal of Medical Sciences**, 4(2), p.83.
- Chao, J. and Terkeltaub, R., 2009. A Critical Reappraisal of Allopurinol Dosing, Safety, and Efficacy for Hyperuricemia in Gout. **Current Rheumatology Reports**, 11(2), pp.135-140.
- Cheuk, D.K., Chiang, A.K., Chan, G.C. and Ha, S.Y., 2017. Urate Oxidase for the Prevention and Treatment of Tumour Lysis Syndrome in Children with Cancer. **Cochrane Database of Systematic Reviews**, (3).
- Cheung, W.L., Hon, K.L., Fung, C.M. and Leung, A.K., 2020. Tumor Lysis Syndrome in Childhood Malignancies. **Drugs in Context**, 9.
- Chung, H.H. and Tsyvkin, E., 2016. Tumor Lysis Syndrome. **Hospital Medicine Clinics**, 5(3), pp.425-438
- Coiffier, B., Altman, A., Pui, C.H., Younes, A. and Cairo, M.S., 2008. Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: an Evidence-Based Review. **Journal of Clinical Oncology**, 26(16), pp.2767-2778.
- Cortes, Jorge, Joseph O. Moore, Richard T. Maziarz, Meir Wetzler, Michael Craig, Jeffrey Matous, Selina Luger et al. Control of Plasma Uric Acid in Adults at Risk for Tumor Lysis Syndrome: Efficacy and Safety of Rasburicase Alone and Rasburicase Followed by Allopurinol Compared with Allopurinol Alone—Results of a Multicenter Phase III Study. **Journal of Clinical Oncology** 28, no. 27 (2010): 4207.
- Currie, W.J., Turner, P. and Young, J.H., 1978. Evaluation of Once a Day Allopurinol Administration in Man. **British Journal of Clinical Pharmacology**, 5(1), p.90.
- Day, R.O., Graham, G.G., Hicks, M., McLachlan, A.J., Stocker, S.L. and Williams, K.M., 2007. Clinical Pharmacokinetics and Pharmacodynamics of Allopurinol and Oxypurinol. **Clinical Pharmacokinetics**, 46(8), pp.623-644.
- De Souza, V.C., Rabilloud, M., Cochat, P., Selistre, L., Hadj-Aissa, A., Kassai, B., Ranchin, B., Berg, U., Herthelius, M. and Dubourg, L., 2012. Schwartz Formula: Is One K-Coefficient Adequate for All Children?. **PloS one**, 7(12), p.e53439.

- Den Bakker, E., Gemke, R.J. and Bökenkamp, A., 2018. Endogenous Markers for Kidney Function in Children: a Review. **Critical Reviews in Clinical Laboratory Sciences**, 55(3), pp.163-183.
- Depkes. 2009. Klasifikasi Usia Pediatrik (www.depkes.go.id)
- Dilanthi, H.W., Kularatnam, G.A.M., Jayasena, S., Jasinge, E., Samaranayake, D.B.D.L. and Wickramasinghe, V.P., 2017. Validity of The Use of Schwartz Formula Against Creatinine Clearance in The Assessment of Renal Functions in Children. **Sri Lanka Journal of Child Health**, 46(2).
- Dinnel, J., Moore, B.L., Skiver, B.M. and Bose, P., 2015. Rasburicase in the Management of Tumor Lysis: an Evidence-Based Review of its Place in Therapy. **Core Evidence**, 10, p.23.
- Durani, U. and Hogan, W.J., 2019. Emergencies in Haematology: Tumour Lysis Syndrome. **British journal of haematology**, 188(4), pp.494-500.
- Edeani, A. and Shirali, A., 2016. Tumor Lysis Syndrome. **American Society of Nephrology**, pp 1-8.
- Firwana, B.M., Hasan, R., Hasan, N., Alahdab, F., Alnahhas, I., Hasan, S. and Varon, J., 2012. Tumor Lysis Syndrome: a Systematic Review of Case Series and Case Reports. **Postgraduate Medicine**, 124(2), pp.92-101.
- FDA. 2017. Uloric (Febuxostat) Tablet for Oral Use.
- Friedman, M., Patel, P.R. and Rondelli, D., 2015, June. A Focused Review of the Pathogenesis, Diagnosis, and Management of Tumor Lysis Syndrome for the Interventional Radiologist. **In Seminars in Interventional Radiology** (Vol. 32, No. 02, pp. 231-236). Thieme Medical Publishers.
- Giammarco, S., Chiusolo, P., Piccirillo, N., Di Giovanni, A., Metafuni, E., Laurenti, L., Sica, S. and Pagano, L., 2017. Hyperleukocytosis and Leukostasis: Management of a Medical Emergency. **Expert Review of Hematology**, 10(2), pp.147-154.
- Goldman, S.C., Holcenberg, J.S., Finklestein, J.Z., Hutchinson, R., Kreissman, S., Johnson, F.L., Tou, C., Harvey, E., Morris, E. and Cairo, M.S., 2001. A Randomized Comparison between Rasburicase and Allopurinol in Children with Lymphoma or Leukemia at High Risk for Tumor Lysis: Presented in Part at The American Society Of Hematology Conference in Miami Beach, FL. **Blood**, 97(10), pp.2998-3003.
- Gucalp, R., Dutcher, J. 2017. **Oncologic Emergencies. In: Longo, D. Harrison's Hematology and Oncology.** Mc-Graw Hills Company, pp 642-656.

- Hashemi, A., Shahvazian, N., Zarezadeh, A., Shakiba, M. and Atefi, A., 2010. Frequency of Tumor Lysis Syndrome in Aggressive and Slow Introduction Chemotherapy in Children with ALL.
- Held-Warmkessel, J., 2010. Preventing & Managing Tumor Lysis Syndrome.
- Helmy, S.A. and El-Bedaiwy, H.M., 2014. Pharmacokinetics and Comparative Bioavailability of Allopurinol Formulations in Healthy Subjects. **Clinical Pharmacology in Drug Development**, 3(5), pp.353-357.
- Henry, M. and Sung, L., 2015. Supportive Care in Pediatric Oncology: Oncologic Emergencies and Management of Fever and Neutropenia. **Pediatric Clinics**, 62(1), pp.27-46.
- Hoff, L.S., Goldenstein-Schainberg, C. and Fuller, R., 2020. Nephrolithiasis in Gout: Prevalence and Characteristics of Brazilian Patients. **Advances in Rheumatology**, 60.
- Howard, S.C., Pui, C.H. and Ribeiro, R.C., 2014. Tumor Lysis Syndrome. **In Renal Disease in Cancer Patients**. Academic Press. pp. 39-64.
- Howard, S.C., Jones, D.P. and Pui, C.H., 2018. The Tumor Lysis Syndrome (vol 364, pg 1844, 2011). **New England Journal Of Medicine**, 379(11), pp.1094-1094.
- Howard, S., 2019. Tumor Lysis Syndrome Management in Community Oncology Settings.
- Howard, S., 2020. Tumor Lysis Syndrome. In: **Clinical Oncology**. 36<sup>th</sup> edition. pp.572-580.
- Imam, H., Ibrahim, H., Hoong, N., Thomas, T. 2018. **Paediatric Protocols for Malaysian Hospitals 4<sup>th</sup> edition**, pp 404-411.
- Jones, G.L., Will, A., Jackson, G.H., Webb, N.J., Rule, S. and British Committee for Standards in Haematology, 2015. Guidelines for the Management of Tumour Lysis Syndrome in Adults and Children with Haematological Malignancies on Behalf of The British Committee for Standards in Haematology. **British Journal of Haematology**, 169(5), pp.661-671.
- Jordan, A. and Gresser, U., 2018. Side Effects and Interactions of the Xanthine Oxidase Inhibitor Febuxostat. **Pharmaceuticals**, 11(2), p.51.
- Kamel, B., Graham, G.G., Williams, K.M., Pile, K.D. and Day, R.O., 2017. Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat. **Clinical Pharmacokinetics**, 56(5), pp.459-475.
- Kaplow, R. and Iyere, K., 2016. Recognizing and Preventing Tumor Lysis Syndrome. **Nursing 2019**, 46(11), pp.26-32.
- Kikuchi, A., Kigasawa, H., Tsurusawa, M., Kawa, K., Kikuta, A., Tsuchida, M., Nagatoshi, Y., Asami, K., Horibe, K., Makimoto, A. and Tsukimoto, I., 2009. A Study of Rasburicase

for the Management of Hyperuricemia in Pediatric Patients with Newly Diagnosed Hematologic Malignancies at High Risk for Tumor Lysis Syndrome. **International Journal of Hematology**, 90(4), pp.492-500.

- Kim, S., Yang, E., Lim, Y., Kim, S. 2017. Spontaneous Tumor Lysis Syndrome Presenting Acute Kidney Injury with Extreme Hyperuricemia and Urinary Stone: a Rare Case of Spontaneous Lysis Syndrome. **Child Kidney Disease** 2017; 21(1): 31-34.
- Kishimoto, K., Kobayashi, R., Hori, D., Sano, H., Suzuki, D. and Kobayashi, K., 2017. Febuxostat as a Prophylaxis for Tumor Lysis Syndrome in Children with Hematological Malignancies. **Anticancer Research**, 37(10), pp.5845-5849.
- Kumar, V., Abbas, A., Fausto, N., Robbins, S. and Cotran, R. 2005. **Robbins and Cotran Pathologic Basis Of Disease**. 7th ed. Philadelphia: Elsevier Saunders, p.29.
- Kumar, V., Abbas, A., Aster, J. 2018. **Buku Ajar Patologi Dasar Robbins Edisi ke-10**. Elsevier, pp 31-40.
- Kunstel, K.L., 2016. Oncologic Emergencies. **Physician Assistant Clinics**, 1(3), pp.397-408.
- Lameire, N., 2014. Nephrotoxicity of Recent Anti-Cancer Agents. **Clinical Kidney Journal**, 7(1), pp.11-22.
- Latcha, S.M., Krishnaprasadh, D., Murugapriya, P. and Scott, J.X., 2015. Single Dose Rasburicase in the Management of Tumor Lysis Syndrome in Childhood Acute Lymphoblastic Leukemia: a Case Series. **Indian Journal of Nephrology**, 25(2), p.91.
- Lee, J.S., Won, J., Kwon, O.C., Lee, S.S., Oh, J.S., Kim, Y.G., Lee, C.K., Yoo, B. and Hong, S., 2019. Hepatic Safety of Febuxostat Compared with Allopurinol in Gout Patients with Fatty Liver Disease. **The Journal of Rheumatology**, 46(5), pp.527-531.
- Li, H.C.W., Chung, O.K.J., Tam, C.J. and Chiu, S.Y., 2015. Effective Prevention and Management of Tumor Lysis Syndrome in Children with Cancer: the Important Contributions of Pediatric Oncology Nurses. **Journal of Pediatric Oncology Nursing**, 32(4), pp.209-218.
- Ly, T.T.T. and Winokur, E.J., 2019. Tumor Lysis Syndrome: A Practical Guide for Nurse Practitioners. **The Journal for Nurse Practitioners**, 15(9), pp.636-639.
- Loebel, W.Y. and Scott, J.T., 1974. Withdrawal of Allopurinol in Patients With Gout. **Annals of the Rheumatic Diseases**, 33(4), p.304.
- Maie, K., Yokoyama, Y., Kurita, N., Minohara, H., Yanagimoto, S., Hasegawa, Y., Homma, M. and Chiba, S., 2014. Hypouricemic Effect and Safety of Febuxostat Used for Prevention of Tumor Lysis Syndrome. **SpringerPlus**, 3(1), p.501.

- Malaguarnera, G., Giordano, M. and Malaguarnera, M., 2012. Rasburicase for the Treatment of Tumor Lysis in Hematological Malignancies. **Expert Review of Hematology**, 5(1), pp.27-38.
- Małyszko, J., Kozłowska, K., Kozłowski, L. and Małyszko, J., 2017. Nephrotoxicity of Anticancer Treatment. **Nephrology Dialysis Transplantation**, 32(6), pp.924-936.
- Manuel, J. 2019. Tumour Lysis Syndrome. **Medicina Clinica**. 152(10), pp 397-404.
- Marsh, A., Agrawal, A., Feusner, J. 2015. Tumor Lysis Syndrome. In: **Supportive Care in Pediatric Oncology a Practical Evidence-Based Approach**. pp 43-56.
- McBride, A. and Westervelt, P., 2012. Recognizing and Managing the Expanded Risk of Tumor Lysis Syndrome in Hematologic and Solid Malignancies. **Journal of Hematology & Oncology**. 5(1), p.75.
- McDonagh, E.M., Thorn, C.F., Callaghan, J.T., Altman, R.B. and Klein, T.E., 2014. Pharmgkb Summary: Uric Acid-Lowering Drugs Pathway, Pharmacodynamics. **Pharmacogenetics and genomics**, 24(9), p.464.
- Micho, H., Mohammed, Y., Hailu, D. and Genet, S., 2018. Evaluation and Characterization of Tumor Lysis Syndrome before and after Chemotherapy among Pediatric Oncology Patients in Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia. **BMC Hematology**, 18(1), p.22.
- Mika, D., Ahmad, S. and Guruvayoorappan, C., 2012. Tumour Lysis Syndrome: Implications for Cancer Therapy. **Asian Pac J Cancer Prev**, 13(8), pp.3555-60.
- Miller, M. 2016. *Gout and Hyperuricemia*. In: Chisholm, M., Schwinghammer, T., Wells, B., Malone, P., Kolesar, J., Dipiro, J. **Pharmacotherapy Principles and Practice** Fourth Edition. Mc-Graw Hills Company. pp 901-910.
- Min, H.K., Lee, B., Kwok, S.K., Ju, J.H., Kim, W.U., Park, Y.M. and Park, S.H., 2015. Allopurinol Hypersensitivity Syndrome in Patients with Hematological Malignancies: Characteristics and Clinical Outcomes. **The Korean journal of internal medicine**, 30(4), p.521.
- Mirrakhimov, A.E., Voore, P., Khan, M. and Ali, A.M., 2015. Tumor Lysis Syndrome: a Clinical Review. **World Journal of Critical Care Medicine**, 4(2), p.130.
- Naeem B, Moorani KN, Anjum M, Imam U. Tumor Lysis Syndrome in Pediatric Acute Lymphoblastic Leukemia at Tertiary Care Center. **Pak Journal Med Sci**. 2019;35(4):899-904.
- Namendys-Silva, S.A., Arredondo-Armenta, J.M., Plata-Menchaca, E.P., Guevara-García, H., García-Guillén, F.J., Rivero-Sigarroa, E. and Herrera-Gómez, A., 2015. Tumor Lysis

- Syndrome in the Emergency Department: Challenges and Solutions. **Open Access Emergency Medicine: OAEM**, 7, p.39.
- Navolanic, P.M., Pui, C.H., Larson, R.A., Bishop, M.R., Pearce, T.E., Cairo, M.S., Goldman, S.C., Jeha, S.C., Shanholtz, C.B., Leonard, J.P. and McCubrey, J.A., 2003. Elitek™–Rasburicase: an Effective Means to Prevent and Treat Hyperuricemia Associated with Tumor Lysis Syndrome, a Meeting Report, Dallas, Texas, January 2002. **Leukemia**, 17(3), p.499.
- Nicolaysen, A., 2020. Nephrotoxic Chemotherapy Agents: Old and New. **Advances in Chronic Kidney Disease**, 27(1), pp.38-49.
- Pagana, K., Pagana, T., Pagana, T. 2019. **Mosby's Diagnostic and Laboratory Test Reference**. 14<sup>th</sup> Edition. Elsevier, pp 899.
- Park, M., Yoon, E., Lim, Y.H., Kim, H., Choi, J. and Yoon, H.J., 2015. Renal Hyperfiltration as a Novel Marker of All-Cause Mortality. **Journal of the American Society of Nephrology**, 26(6), pp.1426-1433.
- Perazella, M.A., 2012. Onco-Nephrology: Renal Toxicities of Chemotherapeutic Agents. **Clinical Journal of the American Society of Nephrology**, 7(10), pp.1713-1721.
- Pession, A., Melchionda, F. and Castellini, C., 2008. Pitfalls, Prevention, and Treatment of Hyperuricemia during Tumor Lysis Syndrome in the Era of Rasburicase (Recombinant Urate Oxidase). **Biologics: Targets & Therapy**, 2(1), p.129.
- Puri, I., Sharma, D., Gunturu, K.S. and Ahmed, A.A., 2020. Diagnosis and Management of Tumor Lysis Syndrome. **Journal of Community Hospital Internal Medicine Perspectives**, 10(3), pp.269-272.
- Rastegar, M., Kitchlu, A. And Shirali, A.C., 2019. Tumor Lysis Syndrome. **Onco-Nephrology E-Book**, P.275.
- Renyi, I., Bardi, E., Udvardi, E., Kovacs, G., Bartyik, K., Kajtar, P., Masat, P., Nagy, K., Galantai, I. and Kiss, C., 2007. Prevention and Treatment of Hyperuricemia with Rasburicase in Children with Leukemia and Non-Hodgkin's Lymphoma. **Pathology and Oncology Research**, 13(1), pp.57-62.
- Russel, T., Kram, D. 2020. Tumor Lysis Syndrome. **American Academy of Pediatrics**, 41(1), pp.20-26.
- Seki, M., Nakayama, M., Sakoh, T., Yoshitomi, R., Fukui, A., Katafuchi, E., Tsuda, S., Nakano, T., Tsuruya, K. and Kitazono, T., 2019. Blood Urea Nitrogen is Independently

- Associated with Renal Outcomes in Japanese Patients with Stage 3–5 Chronic Kidney Disease: a Prospective Observational Study. **BMC nephrology**, 20(1), p.115.
- Schonder, K. 2016. **Pharmacotherapy Principles and Practice**. McGraw-Hill Education.
- Sevinier, B., Demirkaya, M., Baytan, B. and Gunes, A.M., 2011. Hyperuricemia and Tumor Lysis Syndrome in Children with Non-Hodgkin's Lymphoma and Acute Lymphoblastic Leukemia. **Turkish Journal of Hematology**, 28(1).
- Shargel, L., Pong, S., Yu, A. 2012. Alih Bahasa Fasich, Budi Suprapti. **Biofarmasetika dan Farmakokinetika Terapan**. Edisi kelima. Airlangga University Press, pp 1-3.
- Smelcerovic, A., Tomovic, K., Smelcerovic, Z., Petronijevic, Z., Kocic, G., Tomasic, T., Jakopin, Z. and Anderluh, M., 2017. Xanthine Oxidase Inhibitors beyond Allopurinol and Febuxostat; an Overview and Selection of Potential Leads Based on in Silico Calculated Physico-Chemical Properties, Predicted Pharmacokinetics and Toxicity. **European Journal of Medicinal Chemistry**, 135, pp.491-516.
- Strauss, P.Z., Hamlin, S.K. and Dang, J., 2017. Tumor Lysis Syndrome: a Unique Solute Disturbance. **Nursing Clinics**, 52(2), pp.309-320.
- Sury, K., 2019. Update on the Prevention and Treatment of Tumor Lysis Syndrome. **Journal of Onco-Nephrology**, 3(1), pp.19-30.
- Takai, M., Yamauchi, T., Ookura, M., Matsuda, Y., Tai, K., Kishi, S., Yoshida, A., Iwasaki, H., Nakamura, T. and Ueda, T., 2014. Febuxostat for Management of Tumor Lysis Syndrome Including its Effects on Levels of Purine Metabolites in Patients with Hematological Malignancies-A Single Institution's, Pharmacokinetic and Pilot Prospective Study. **Anticancer Research**, 34(12), pp.7287-7296.
- Tambaro, F.P. and Wierda, W.G., 2020. Tumour Lysis Syndrome in Patients with Chronic Lymphocytic Leukaemia Treated with BCL-2 Inhibitors: Risk Factors, Prophylaxis, and Treatment Recommendations. **The Lancet Haematology**, 7(2), pp.e168-e176.
- Tazi, I., Nafil, H., Elhoudzi, J., Mahmal, L. and Harif, M., 2011. Management of Pediatric Tumor Lysis Syndrome. **Arab Journal of Nephrology and Transplantation**, 4(3), pp.147-154.
- Tiu, R., Mountantonakis, S., Dunbar, A., Schreiber, M. 2007. Tumor Lysis Syndrome. **Research Gate**, 33(4), pp. 397-407.
- Trifilio, S.M., Pi, J., Zook, J., Golf, M., Coyle, K., Greenberg, D., Newman, D., Koslosky, M. and Mehta, J., 2011. Effectiveness Of A Single 3-mg Rasburicase Dose for the Management of Hyperuricemia in Patients with Hematological Malignancies. **Bone Marrow Transplantation**, 46(6), p.800.

- Ueng, S., 2005, July. Rasburicase (Elitek): a Novel Agent for Tumor Lysis Syndrome. In Baylor University Medical Center Proceedings (Vol. 18, No. 3, pp. 275-279). Taylor & Francis.
- Vadhan-Raj, S., Fayad, L.E., Fanale, M.A., Pro, B., Rodriguez, A., Hagemester, F.B., Bueso-Ramos, C.E., Zhou, X., McLaughlin, P.W., Fowler, N. and Shah, J., 2011. A Randomized Trial of a Single-Dose Rasburicase versus Five-Daily Doses in Patients at Risk For Tumor Lysis Syndrome. **Annals of Oncology**, 23(6), pp.1640-1645.
- Vallerand, A.H., Sanoski, C., 2019. **Davis's Drug Guide for Nurses**. 16<sup>th</sup> Edition. FA Davis, pp. 125-126.
- Villas, J.M.C., 2019. Tumour lysis syndrome. **Medicina Clínica (English Edition)**, 152(10), pp.397-404.
- Wagner, J. and Arora, S., 2017. Oncologic Metabolic Emergencies. **Hematology/Oncology Clinics**, 31(6), pp.941-957.
- Wagner, J., Arora, S. 2019. Oncologic Metabolic Emergencies. Emergency Medicine Clinic. White, W.B., Saag, K.G., Becker, M.A., Borer, J.S., Gorelick, P.B., Whelton, A., Hunt, B., Castillo, M. and Gunawardhana, L., 2018. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. **New England Journal of Medicine**, 378(13), pp.1200-1210.
- Williams, S.M. and Killeen, A.A., 2019. Tumor Lysis Syndrome. **Archives of Pathology and Laboratory Medicine**, 143(3), pp.386-393.
- Wilson, F.P. and Berns, J.S., 2012. Onco-Nephrology: Tumor Lysis Syndrome. **Clinical Journal of the American Society of Nephrology**, 7(10), pp.1730-1739.
- Wilson, F.P. and Berns, J.S., 2014. Tumor Lysis Syndrome: New Challenges and Recent Advances. **Advances In Chronic Kidney Disease**, 21(1), pp.18-26.
- Xu, L., Shi, Y., Zhuang, S. and Liu, N., 2017. Recent Advances on Uric Acid Transporters. **Oncotarget**, 8(59), p.100852.
- Yang, C.Y., Chen, C.H., Deng, S.T., Huang, C.S., Lin, Y.J., Chen, Y.J., Wu, C.Y., Hung, S.I. and Chung, W.H., 2015. Allopurinol Use and Risk of Fatal Hypersensitivity Reactions: a Nationwide Population-Based Study in Taiwan. **JAMA internal medicine**, 175(9), pp.1550-1557.
- Zivin, S.P., Elias, Y. and Ray Jr, C.E., 2015, March. Tumor Lysis Syndrome and Primary Hepatic Malignancy: Case Presentation and Review of The Literature. **In Seminars in Interventional Radiology** (Vol. 32, No. 01, pp. 003-009). Thieme Medical Publishers.

Zonfrillo, M.R., 2009. Management of Pediatric Tumor Lysis Syndrome in the Emergency Department. **Emergency Medicine Clinics of North America**, 27(3), pp.497-504.